Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver

Hiroya Yamada, Koji Suzuki, Naohiro Ichino, Yoshitaka Ando, Akira Sawada, Keisuke Osakabe, Keiko Sugimoto, Koji Ohashi, Ryouji Teradaira, Takashi Inoue, Nobuyuki Hamajima, Shuji Hashimoto

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Background: In many industrialized countries, non-alcoholic fatty liver disease (NAFLD) is recognized as an important disease that increases the risk of cardiovascular disease, type-2 diabetes, and metabolic syndrome. Most people with NAFLD are asymptomatic, and the disease is discovered incidentally during clinical laboratory tests. Present screening methods for NAFLD use ultrasound, and CT scans that are time-consuming, and a simple screening method for NAFLD is needed. In this study, we investigated whether serum miRNAs are associated with NAFLD and assessed the potential of serum miRNAs as a biomarker for NAFLD. Methods: We assessed intrahepatic fat by ultrasound scan, and the serum levels of five miRNAs (miR-21, miR-34a, miR-122, miR-145, and miR-451), which help regulate cholesterol and fatty acid homeostasis in liver tissue, by real-time PCR in a cross-sectional sample of 403 participants who attended health examinations. Results: Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis. Conclusion: Serum levels of miRNAs, particularly miR-122, may be a useful biomarker for NAFLD.

Original languageEnglish
Pages (from-to)99-103
Number of pages5
JournalClinica Chimica Acta
Volume424
DOIs
Publication statusPublished - 03-09-2013

Fingerprint

Fatty Liver
MicroRNAs
Liver
Serum
Biomarkers
Asymptomatic Diseases
Screening
Non-alcoholic Fatty Liver Disease
Ultrasonics
Clinical laboratories
Developed Countries
Type 2 Diabetes Mellitus
Real-Time Polymerase Chain Reaction
Computerized tomography
Homeostasis
Cardiovascular Diseases
Fatty Acids
Medical problems
Fats
Cholesterol

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

@article{fbec15eba02845e980c67c9ee1c6cb61,
title = "Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver",
abstract = "Background: In many industrialized countries, non-alcoholic fatty liver disease (NAFLD) is recognized as an important disease that increases the risk of cardiovascular disease, type-2 diabetes, and metabolic syndrome. Most people with NAFLD are asymptomatic, and the disease is discovered incidentally during clinical laboratory tests. Present screening methods for NAFLD use ultrasound, and CT scans that are time-consuming, and a simple screening method for NAFLD is needed. In this study, we investigated whether serum miRNAs are associated with NAFLD and assessed the potential of serum miRNAs as a biomarker for NAFLD. Methods: We assessed intrahepatic fat by ultrasound scan, and the serum levels of five miRNAs (miR-21, miR-34a, miR-122, miR-145, and miR-451), which help regulate cholesterol and fatty acid homeostasis in liver tissue, by real-time PCR in a cross-sectional sample of 403 participants who attended health examinations. Results: Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis. Conclusion: Serum levels of miRNAs, particularly miR-122, may be a useful biomarker for NAFLD.",
author = "Hiroya Yamada and Koji Suzuki and Naohiro Ichino and Yoshitaka Ando and Akira Sawada and Keisuke Osakabe and Keiko Sugimoto and Koji Ohashi and Ryouji Teradaira and Takashi Inoue and Nobuyuki Hamajima and Shuji Hashimoto",
year = "2013",
month = "9",
day = "3",
doi = "10.1016/j.cca.2013.05.021",
language = "English",
volume = "424",
pages = "99--103",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. / Yamada, Hiroya; Suzuki, Koji; Ichino, Naohiro; Ando, Yoshitaka; Sawada, Akira; Osakabe, Keisuke; Sugimoto, Keiko; Ohashi, Koji; Teradaira, Ryouji; Inoue, Takashi; Hamajima, Nobuyuki; Hashimoto, Shuji.

In: Clinica Chimica Acta, Vol. 424, 03.09.2013, p. 99-103.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver

AU - Yamada, Hiroya

AU - Suzuki, Koji

AU - Ichino, Naohiro

AU - Ando, Yoshitaka

AU - Sawada, Akira

AU - Osakabe, Keisuke

AU - Sugimoto, Keiko

AU - Ohashi, Koji

AU - Teradaira, Ryouji

AU - Inoue, Takashi

AU - Hamajima, Nobuyuki

AU - Hashimoto, Shuji

PY - 2013/9/3

Y1 - 2013/9/3

N2 - Background: In many industrialized countries, non-alcoholic fatty liver disease (NAFLD) is recognized as an important disease that increases the risk of cardiovascular disease, type-2 diabetes, and metabolic syndrome. Most people with NAFLD are asymptomatic, and the disease is discovered incidentally during clinical laboratory tests. Present screening methods for NAFLD use ultrasound, and CT scans that are time-consuming, and a simple screening method for NAFLD is needed. In this study, we investigated whether serum miRNAs are associated with NAFLD and assessed the potential of serum miRNAs as a biomarker for NAFLD. Methods: We assessed intrahepatic fat by ultrasound scan, and the serum levels of five miRNAs (miR-21, miR-34a, miR-122, miR-145, and miR-451), which help regulate cholesterol and fatty acid homeostasis in liver tissue, by real-time PCR in a cross-sectional sample of 403 participants who attended health examinations. Results: Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis. Conclusion: Serum levels of miRNAs, particularly miR-122, may be a useful biomarker for NAFLD.

AB - Background: In many industrialized countries, non-alcoholic fatty liver disease (NAFLD) is recognized as an important disease that increases the risk of cardiovascular disease, type-2 diabetes, and metabolic syndrome. Most people with NAFLD are asymptomatic, and the disease is discovered incidentally during clinical laboratory tests. Present screening methods for NAFLD use ultrasound, and CT scans that are time-consuming, and a simple screening method for NAFLD is needed. In this study, we investigated whether serum miRNAs are associated with NAFLD and assessed the potential of serum miRNAs as a biomarker for NAFLD. Methods: We assessed intrahepatic fat by ultrasound scan, and the serum levels of five miRNAs (miR-21, miR-34a, miR-122, miR-145, and miR-451), which help regulate cholesterol and fatty acid homeostasis in liver tissue, by real-time PCR in a cross-sectional sample of 403 participants who attended health examinations. Results: Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis. Conclusion: Serum levels of miRNAs, particularly miR-122, may be a useful biomarker for NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=84879448114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879448114&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2013.05.021

DO - 10.1016/j.cca.2013.05.021

M3 - Article

C2 - 23727030

AN - SCOPUS:84879448114

VL - 424

SP - 99

EP - 103

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -